CURATIS N AG (CURN) - Total Assets

Latest as of June 2025: CHF54.52 Million CHF ≈ $68.93 Million USD

Based on the latest financial reports, CURATIS N AG (CURN) holds total assets worth CHF54.52 Million CHF (≈ $68.93 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

CURATIS N AG - Total Assets Trend (2002–2024)

This chart illustrates how CURATIS N AG's total assets have evolved over time, based on quarterly financial data. Also see CURN stock market capitalisation for the company's overall valuation and market capitalisation.

CURATIS N AG - Asset Composition Analysis

Current Asset Composition (December 2024)

CURATIS N AG's total assets of CHF54.52 Million consist of 10.6% current assets and 89.4% non-current assets. Review CURN current and long-term liabilities to assess the company's total debt and financial obligations.

Asset Category Amount (CHF) % of Total Assets
Cash & Equivalents CHF3.01 Million 5.4%
Accounts Receivable CHF1.56 Million 2.8%
Inventory CHF1.32 Million 2.4%
Property, Plant & Equipment CHF0.00 0.0%
Intangible Assets CHF49.38 Million 88.9%
Goodwill CHF0.00 0.0%

Asset Composition Trend (2002–2024)

This chart illustrates how CURATIS N AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See CURATIS N AG (CURN) stock price for real-time trading data and today's change.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: CURATIS N AG's current assets represent 10.6% of total assets in 2024, a decrease from 36.2% in 2002.
  • Cash Position: Cash and equivalents constituted 5.4% of total assets in 2024, down from 6.5% in 2002.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 88.0% of total assets, an increase from 3.0% in 2002.
  • Asset Diversification: The largest asset category is intangible assets at 88.9% of total assets.

CURATIS N AG Competitors by Total Assets

Key competitors of CURATIS N AG based on total assets are shown below.

Company Country Total Assets
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Germany €1.60 Trillion
GALDERMA GROUP AG
NYSE:GALDY
USA $13.39 Billion
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
USA $15.42 Trillion
Beijing Tongrentang Co Ltd
SHG:600085
China CN¥31.82 Billion
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Changchun High & New Technology Industries Group Inc
SHE:000661
China CN¥30.77 Billion
Neuland Laboratories Limited
NSE:NEULANDLAB
India Rs29.30 Billion
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
China CN¥17.01 Billion

CURATIS N AG - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.50 0.92 1.09
Quick Ratio 1.07 0.72 1.09
Cash Ratio 0.62 0.51 0.00
Working Capital CHF1.65 Million CHF-555.00K CHF17.00K

CURATIS N AG - Advanced Valuation Insights

This section examines the relationship between CURATIS N AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.06
Latest Market Cap to Assets Ratio 1.61
Asset Growth Rate (YoY) 46180.0%
Total Assets CHF55.54 Million
Market Capitalization $89.64 Million USD

Valuation Analysis

Above Book Valuation: The market values CURATIS N AG's assets above their book value (1.61x), reflecting positive investor sentiment about the company's future prospects.

Rapid Asset Growth: CURATIS N AG's assets grew by 46180.0% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for CURATIS N AG (2002–2024)

The table below shows the annual total assets of CURATIS N AG from 2002 to 2024.

Year Total Assets Change
2024-12-31 CHF55.54 Million
≈ $70.21 Million
+46180.00%
2023-12-31 CHF120.00K
≈ $151.71K
-99.15%
2022-12-31 CHF14.05 Million
≈ $17.76 Million
+10227.94%
2021-12-31 CHF136.00K
≈ $171.94K
+7.09%
2020-12-31 CHF127.00K
≈ $160.56K
-94.16%
2019-12-31 CHF2.17 Million
≈ $2.75 Million
-0.73%
2018-12-31 CHF2.19 Million
≈ $2.77 Million
-67.24%
2017-12-31 CHF6.68 Million
≈ $8.45 Million
-5.70%
2016-12-31 CHF7.09 Million
≈ $8.96 Million
-11.01%
2015-12-31 CHF7.97 Million
≈ $10.07 Million
-19.95%
2014-12-31 CHF9.95 Million
≈ $12.58 Million
-14.75%
2013-12-31 CHF11.67 Million
≈ $14.76 Million
-39.27%
2012-12-31 CHF19.22 Million
≈ $24.30 Million
+56.62%
2011-12-31 CHF12.27 Million
≈ $15.52 Million
-8.15%
2010-12-31 CHF13.36 Million
≈ $16.89 Million
+61.52%
2009-12-31 CHF8.27 Million
≈ $10.46 Million
+62.45%
2008-12-31 CHF5.09 Million
≈ $6.44 Million
-45.61%
2007-12-31 CHF9.36 Million
≈ $11.84 Million
-32.69%
2006-12-31 CHF13.91 Million
≈ $17.58 Million
-59.87%
2005-12-31 CHF34.66 Million
≈ $43.82 Million
-41.97%
2004-12-31 CHF59.73 Million
≈ $75.51 Million
-16.27%
2003-12-31 CHF71.33 Million
≈ $90.18 Million
+3.32%
2002-12-31 CHF69.04 Million
≈ $87.29 Million
--

About CURATIS N AG

SW:CURN Switzerland Drug Manufacturers - Specialty & Generic
Market Cap
$123.75 Million
CHF97.88 Million CHF
Market Cap Rank
#19682 Global
#189 in Switzerland
Share Price
CHF19.00
Change (1 day)
-2.31%
52-Week Range
CHF11.30 - CHF26.00
All Time High
CHF891.52
About

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more